Published in Radiother Oncol on October 01, 1995
Biological-effective versus conventional dose volume histograms correlated with late genitourinary and gastrointestinal toxicity after external beam radiotherapy for prostate cancer: a matched pair analysis. BMC Cancer (2003) 0.99
Evaluation of late rectal toxicity after conformal radiotherapy for prostate cancer: a comparison between dose-volume constraints and NTCP use. Strahlenther Onkol (2009) 0.86
Comparison of treatment techniques for conformal radiotherapy of the prostate using dose-volume histograms and normal tissue complication probabilities. Radiother Oncol (1996) 0.77
Characterization of a new radiochromic three-dimensional dosimeter. Med Phys (2006) 3.46
Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol (2003) 3.10
A comprehensive evaluation of the PRESAGE/optical-CT 3D dosimetry system. Med Phys (2009) 2.86
Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int (2003) 2.29
Particulate matter in polluted air may increase biomarkers of inflammation in mouse brain. Neurotoxicology (2005) 2.25
Polymer gel dosimetry. Phys Med Biol (2010) 2.19
Perfusion of the spleen with blood containing prostaglandin E1: transmitter liberation and uptake. Proc R Soc Lond B Biol Sci (1969) 2.11
Detection of micrometastases in patients with primary breast cancer. Lancet (1983) 2.07
Fast, high-resolution 3D dosimetry utilizing a novel optical-CT scanner incorporating tertiary telecentric collimation. Med Phys (2008) 1.77
A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer. Clin Oncol (R Coll Radiol) (2007) 1.75
Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry (2001) 1.65
Intensity modulated radiation therapy: a clinical review. Br J Radiol (2000) 1.62
Prognostic factors in hormone-resistant progressing cancer of the prostate. Ann Oncol (1992) 1.61
The noradrenaline content of the vas deferens of the guinea-pig. Proc R Soc Lond B Biol Sci (1970) 1.58
Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol (2000) 1.54
Radiation dosimetry using polymer gels: methods and applications. Br J Radiol (2000) 1.53
Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol (2003) 1.49
A randomized study of the use of a customized immobilization system in the treatment of prostate cancer with conformal radiotherapy. Radiother Oncol (2000) 1.49
Combination carboplatin and radiotherapy in the management of stage II testicular seminoma: comparison with radiotherapy treatment alone. Radiother Oncol (2001) 1.49
Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment. Radiother Oncol (1997) 1.47
Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localized prostate cancer. Clin Oncol (R Coll Radiol) (2001) 1.46
Use of antisera to epithelial membrane antigen for the cytodiagnosis of malignancy in serous effusions. J Clin Pathol (1981) 1.46
RAPPER: the radiogenomics of radiation toxicity. Clin Oncol (R Coll Radiol) (2013) 1.42
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial. Clin Oncol (R Coll Radiol) (2008) 1.42
Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. Ann Oncol (2013) 1.41
A comparison of conformal and intensity-modulated techniques for oesophageal radiotherapy. Radiother Oncol (2001) 1.40
Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int J Radiat Oncol Biol Phys (1999) 1.39
The effect of antiemetics and reduced radiation fields on acute gastrointestinal morbidity of adjuvant radiotherapy in stage I seminoma of the testis: a randomized pilot study. Clin Oncol (R Coll Radiol) (1997) 1.39
Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen. Br J Cancer (1981) 1.39
A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol (1994) 1.37
Fast, large field-of-view, telecentric optical-CT scanning system for 3D radiochromic dosimetry. J Phys Conf Ser (2010) 1.36
Magnetic resonance imaging (MRI): considerations and applications in radiotherapy treatment planning. Radiother Oncol (1997) 1.35
Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys (2000) 1.34
Epithelial Membrane Antigen. Its use in the cytodiagnosis of malignancy in serous effusions. Am J Clin Pathol (1982) 1.28
Effect of nerve stimulation on the noradrenaline content of the spleen. Proc R Soc Lond B Biol Sci (1966) 1.27
Dynamic contrast-enhanced MRI for prostate cancer localization. Br J Radiol (2009) 1.26
Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol (1997) 1.24
Detection of isolated mammary carcinoma cells in marrow of patients with primary breast cancer. J R Soc Med (1983) 1.17
Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer (2005) 1.15
Simple nontoxic treatment of advanced metastatic seminoma with carboplatin. J Clin Oncol (1989) 1.14
Indirect immunoalkaline phosphatase staining of cytologic smears of serous effusions for tumor marker studies. Acta Cytol (1983) 1.13
Evaluation of three types of reference image data for external beam radiotherapy target localization using digital tomosynthesis (DTS). Med Phys (2007) 1.13
Functional imaging in bulk tissue specimens using optical emission tomography: fluorescence preservation during optical clearing. Phys Med Biol (2007) 1.13
The identification of dopamine in the rabbit's carotid body. Proc R Soc Lond B Biol Sci (1968) 1.11
Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer (2010) 1.11
Individualization of dose prescription based on normal-tissue dose-volume and radiosensitivity data. Int J Radiat Oncol Biol Phys (2001) 1.11
Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging. Radiology (2001) 1.10
No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group. Br J Cancer (1997) 1.10
Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol (2003) 1.09
A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol (1998) 1.08
A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer (2000) 1.08
Correlations between dose-surface histograms and the incidence of long-term rectal bleeding following conformal or conventional radiotherapy treatment of prostate cancer. Int J Radiat Oncol Biol Phys (2001) 1.08
A modified Inflammatory Bowel Disease questionnaire and the Vaizey Incontinence questionnaire are simple ways to identify patients with significant gastrointestinal symptoms after pelvic radiotherapy. Br J Cancer (2005) 1.07
Question of dose, fractionation and technique: ingredients for testing hypofractionation in prostate cancer--the CHHiP trial. Clin Oncol (R Coll Radiol) (2007) 1.07
Strontium-89 (Metastron) versus external beam radiotherapy in patients with painful bone metastases secondary to prostatic cancer: preliminary report of a multicenter trial. UK Metastron Investigators Group. Semin Oncol (1993) 1.06
The impact of clinical factors on the development of late radiation toxicity: results from the Medical Research Council RT01 trial (ISRCTN47772397). Clin Oncol (R Coll Radiol) (2011) 1.04
Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer (1992) 1.03
Improvements in target coverage and reduced spinal cord irradiation using intensity-modulated radiotherapy (IMRT) in patients with carcinoma of the thyroid gland. Radiother Oncol (2001) 1.03
Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Int J Cancer (1998) 1.02
Target volume definition for head and neck intensity modulated radiotherapy: pre-clinical evaluation of PARSPORT trial guidelines. Clin Oncol (R Coll Radiol) (2007) 1.02
Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer (2008) 1.01
Potential improvements in the therapeutic ratio of prostate cancer irradiation: dose escalation of pathologically identified tumour nodules using intensity modulated radiotherapy. Br J Radiol (2002) 1.01
Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol (2009) 1.01
Long-term outcome after percutaneous treatment of transitional cell carcinoma of the renal pelvis. J Urol (1996) 1.00
Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol (1997) 0.99
Dynamics of polymerization in polyacrylamide gel (PAG) dosimeters: (I) ageing and long-term stability. Phys Med Biol (1999) 0.98
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer (2002) 0.98
Optimized MR imaging for polyacrylamide gel dosimetry. Phys Med Biol (2000) 0.97
Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors. J Clin Oncol (1991) 0.97
Preliminary commissioning investigations with the DMOS-RPC optical-CT Scanner. J Phys Conf Ser (2010) 0.96
Accelerated chemotherapy for poor prognosis germ cell tumours. Eur J Cancer (1994) 0.96
Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. Pharmacogenetics (2001) 0.95
Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study. Br J Radiol (1999) 0.95
Computational modeling of nanoscale and microscale particle deposition, retention and dosimetry in the mouse respiratory tract. Inhal Toxicol (2014) 0.95
Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol (1992) 0.95
Radiotherapy planning of the pelvis using distortion corrected MR images: the removal of system distortions. Phys Med Biol (2000) 0.94
Vascular responses and noradrenaline overflows in the isolated blood-perfused cat spleen: some effects of cocaine, normetanephrine and -blocking agents. J Physiol (1972) 0.94
The activity of single-agent carboplatin in advanced seminoma. Eur J Cancer (1992) 0.94
Optimisation of radiotherapy for carcinoma of the parotid gland: a comparison of conventional, three-dimensional conformal, and intensity-modulated techniques. Radiother Oncol (2001) 0.94
Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int J Cancer (1999) 0.94
Distribution of lymph nodes in men with prostatic adenocarcinoma and lymphadenopathy at presentation: a retrospective radiological review and implications for prostate and pelvis radiotherapy. Clin Oncol (R Coll Radiol) (2006) 0.93
Orchidectomy alone for stage I seminoma of the testis. Cancer (1990) 0.93
Dose Verification of Stereotactic Radiosurgery Treatment for Trigeminal Neuralgia with Presage 3D Dosimetry System. J Phys Conf Ser (2010) 0.92
Para-aortic lymphadenectomy after chemotherapy for metastatic non-seminomatous germ cell tumours: prognostic value and therapeutic benefit. Br J Urol (1993) 0.91
High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma. Br J Cancer (1988) 0.91
Spermatocytic seminoma: a clinicopathological review of ten patients. Clin Oncol (R Coll Radiol) (1996) 0.90
Spinal cord compression in prostate cancer: treatment outcome and prognostic factors. Radiother Oncol (1997) 0.89
On the Feasibility of Verification of 3D Dosimetry Near Brachytherapy Sources Using PRESAGE/Optical-CT. J Phys Conf Ser (2010) 0.89
HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease. Br J Cancer (2002) 0.89
Association between leptin receptor gene polymorphisms and early-onset prostate cancer. BJU Int (2003) 0.89
Markers in breast and lung cancer. Ann Clin Biochem (1982) 0.89
Carcinoembryonic antigen estimation in cerebrospinal fluid in patients with metastatic breast cancer. Oncodev Biol Med (1981) 0.89
Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer. Prostate Cancer Prostatic Dis (2002) 0.89
Radical radiotherapy for prostate cancer. Cancer Treat Rev (2003) 0.87
Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma. J Clin Oncol (1995) 0.86
Small-cell carcinoma of the prostate. J R Soc Med (1997) 0.86
Induction of transforming growth factor beta in hormonally treated human prostate cancer. Br J Cancer (1994) 0.86
Detection of occult spinal cord compression with magnetic resonance imaging of the spine. Clin Oncol (R Coll Radiol) (2007) 0.86